ClinicalIntelPulse

Live 402 challenge

Captured by the enrichment pass, not read just now. Prices can change — always read the 402 the endpoint answers with.

{
  "error": "X-PAYMENT header is required",
  "accepts": [
    {
      "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
      "extra": {
        "name": "USD Coin",
        "version": "2"
      },
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "scheme": "exact",
      "network": "base",
      "mimeType": "application/json",
      "resource": "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map",
      "description": "Drug mechanism-of-action + molecular target landscape for any disease — targets in active trials, approved agents by MOA, crowded vs novel mechanisms and first-in-class openings, with key publications. Worldwide. For drug-discovery and VC agents.",
      "maxAmountRequired": "200000",
      "maxTimeoutSeconds": 300
    }
  ],
  "x402Version": 1
}

Accepts

The payment requirements as published to the catalog. Read the live 402 before paying — a price here is a claim, not a quote.

[
  {
    "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
    "extra": {
      "name": "USD Coin",
      "version": "2"
    },
    "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
    "amount": "200000",
    "scheme": "exact",
    "network": "eip155:8453",
    "maxTimeoutSeconds": 300
  },
  {
    "asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
    "extra": {
      "feePayer": "GVJJ7rdGiXr5xaYbRwRbjfaJL7fmwRygFi1H6aGqDveb"
    },
    "payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
    "amount": "200000",
    "scheme": "exact",
    "network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
    "maxTimeoutSeconds": 300
  }
]

Extensions

{
  "bazaar": {
    "info": {
      "input": {
        "type": "http",
        "method": "GET",
        "queryParams": {
          "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
          "condition": "Disease — e.g. \"Treatment-Resistant Depression\" | \"ALS\" | \"Lupus\" | \"Multiple Sclerosis\" | \"Prostate Cancer\"",
          "mechanism": "Optional — specific mechanism to focus on, e.g. \"BTK inhibitor\" | \"IL-17\" | \"CAR-T\""
        }
      },
      "output": {
        "type": "json",
        "example": {
          "query_summary": {
            "condition": "Multiple Sclerosis",
            "mechanism": null
          },
          "key_publications": [
            {
              "year": "2024",
              "title": "BTK inhibitors in progressive MS — mechanisms and clinical data",
              "journal": "Nature Reviews Neurology"
            }
          ],
          "mechanism_landscape": {
            "white_spaces": [
              "Progressive MS neuroprotection",
              "Remyelination",
              "CNS innate immunity",
              "Biomarker-stratified precision approaches"
            ],
            "crowded_spaces": [
              "Anti-CD20 (3 approved, 2 in pipeline)",
              "S1P modulators (4 approved)",
              "Natalizumab analogues"
            ],
            "approved_mechanisms": [
              {
                "moa": "Anti-CD20 (B cell depletion)",
                "drugs": [
                  "Ocrelizumab",
                  "Ofatumumab",
                  "Ublituximab"
                ],
                "notes": "Dominant mechanism for RRMS — 3 approved"
              },
              {
                "moa": "S1P receptor modulator",
                "drugs": [
                  "Fingolimod",
                  "Siponimod",
                  "Ozanimod",
                  "Ponesimod"
                ],
                "notes": "Oral DMT — 4 approved; class mature"
              },
              {
                "moa": "BTK inhibitor",
                "drugs": [],
                "notes": "No approvals yet — 6 agents in Phase 2/3"
              }
            ],
            "pipeline_mechanisms": [
              {
                "moa": "BTK inhibition (CNS-penetrant)",
                "phase": "PHASE3",
                "agents": [
                  "Fenebrutinib (Roche)",
                  "Tolebrutinib (Sanofi)",
                  "Evobrutinib (Merck)"
                ],
                "crowding": "Moderate (3 Phase 3)",
                "differentiation": "Targets microglial activation — may address progressive MS unlike existing agents"
              },
              {
                "moa": "Remyelination (opioid receptor modulation)",
                "phase": "PHASE2",
                "agents": [
                  "Opicinumab (Biogen)"
                ],
                "crowding": "Low",
                "differentiation": "Novel — no approved remyelinating agents"
              }
            ]
          },
          "drug_discovery_implications": "BTK inhibition is the most clinically advanced novel mechanism. CNS penetration and microglial targeting differentiate from older agents. Progressive MS remains the largest unmet need.",
          "first_in_class_opportunities": [
            "BTK inhibitors for progression (if Phase 3 data positive)",
            "Remyelinating agents (no approved class)"
          ]
        }
      }
    },
    "schema": {
      "type": "object",
      "$schema": "https://json-schema.org/draft/2020-12/schema"
    }
  },
  "builder-code": {
    "info": {
      "a": "bc_gxy6qn5p"
    },
    "schema": {
      "type": "object",
      "$schema": "https://json-schema.org/draft/2020-12/schema",
      "properties": {
        "a": {
          "type": "string",
          "pattern": "^[a-z0-9_]{1,32}$",
          "description": "App builder code"
        },
        "s": {
          "type": "array",
          "items": {
            "type": "string",
            "pattern": "^[a-z0-9_]{1,32}$"
          },
          "description": "Service builder codes"
        },
        "w": {
          "type": "string",
          "pattern": "^[a-z0-9_]{1,32}$",
          "description": "Wallet builder code"
        }
      },
      "additionalProperties": false
    }
  }
}

Provenance

Seen in the source catalog

2026-07-01 04:23Z

Last indexed by Roundhouse

2026-07-30 16:00Z

Last enriched (probe, favicon, geo)

2026-09-11 06:45Z

x402 version

2

Max timeout

300s

Liveness probe

HTTP 402